| Name | NG25 |
| Description | NG25 is a potent dual inhibitor of TAK1 and MAP4K2, with IC50s of 149 nM and 21.7 nM, respectively. |
| Cell Research | Breast cancer cells were seeded in 12-well plates at 2?×?10^3 cells per well, then incubated with Dox alone or Dox with NG25 at indicated concentrations after 72?h and then were cultured in fresh medium without drug.?Two weeks later, cells were fixed and stained with methanol/crystal violet for 10?min, and photographed.?Each experiment was performed in triplicates[1]. |
| In vitro | NG25 sensitizes the breast cancer cells to Dox treatment in vitro. This combination may be an effective and feasible therapeutic option maximizing Dox efficacy and meanwhile minimizing Dox side effects in treating breast cancer[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 16.67 mg/mL (31 mM), Sonication is recommended.
|
| Keywords | NG-25 | NG 25 | NG25 | MAP kinase kinase kinase, MEKK, MAPKKK | MAP4K | inhibit | Inhibitor | MAP3K | MAPK Kinase Kinase Kinase |
| Inhibitors Related | Sodium lauryl sulfoacetate | Nomilin | Vemurafenib | CMPD1 | SKLB-163 | MBM-55S | sodium lauroyl-α-hydroxyethyl sulfonate | NQDI-1 | GNE-1858 | Takinib | MK2-IN-3 hydrate | Selonsertib |
| Related Compound Libraries | Apoptosis Compound Library | Neural Regeneration Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Kinase Inhibitor Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library |
United States
